Core Insights - Workday reported quarterly earnings of $2.21 per share, exceeding the Zacks Consensus Estimate of $2.09 per share, and up from $1.75 per share a year ago, representing an earnings surprise of +5.74% [1] - The company achieved revenues of $2.35 billion for the quarter ended July 2025, surpassing the Zacks Consensus Estimate by 0.35% and increasing from $2.09 billion year-over-year [2] - Workday has consistently surpassed consensus EPS and revenue estimates over the last four quarters [2] Earnings Outlook - The sustainability of Workday's stock price movement will depend on management's commentary during the earnings call and future earnings expectations [3][4] - The current consensus EPS estimate for the upcoming quarter is $2.11 on revenues of $2.42 billion, and for the current fiscal year, it is $8.70 on revenues of $9.5 billion [7] Industry Context - The Internet - Software industry, to which Workday belongs, is currently ranked in the top 30% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Workday's performance [5] Stock Performance - Workday shares have underperformed the market, losing about 11.8% since the beginning of the year, while the S&P 500 has gained 8.7% [3] - The estimate revisions trend for Workday was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6]

Group 1 - OSI Systems reported quarterly earnings of $3.24 per share, exceeding the Zacks Consensus Estimate of $3.19 per share, and up from $2.84 per share a year ago, representing an earnings surprise of +1.57% [1] - The company achieved revenues of $504.99 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 2.34% and increasing from $480.91 million year-over-year [2] - OSI has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Group 2 - The stock has gained approximately 33.4% since the beginning of the year, significantly outperforming the S&P 500's gain of 8.7% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to those expectations [4] - The Zacks Rank for OSI is currently 2 (Buy), indicating expectations for the stock to outperform the market in the near future [6] Group 3 - The current consensus EPS estimate for the upcoming quarter is $1.44 on revenues of $369.05 million, and for the current fiscal year, it is $10.02 on revenues of $1.78 billion [7] - The Electronics - Miscellaneous Components industry, to which OSI belongs, is currently ranked in the top 29% of over 250 Zacks industries, suggesting a favorable outlook for the sector [8]

分组1 - Auna S.A. reported quarterly earnings of $0.33 per share, exceeding the Zacks Consensus Estimate of $0.13 per share, and showing a significant increase from $0.03 per share a year ago, resulting in an earnings surprise of +153.85% [1] - The company posted revenues of $309 million for the quarter ended June 2025, which was 3% below the Zacks Consensus Estimate, but an increase from $292 million in the same quarter last year [2] - Auna S.A. has surpassed consensus EPS estimates three times over the last four quarters, but has only topped revenue estimates once in the same period [2] 分组2 - The stock has underperformed the market, losing about 9% since the beginning of the year, while the S&P 500 has gained 9.7% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is $0.20 on revenues of $330.33 million, and for the current fiscal year, it is $0.76 on revenues of $1.2 billion [7] 分组3 - The Zacks Industry Rank indicates that the Medical Services sector is currently in the bottom 37% of over 250 Zacks industries, suggesting potential challenges for stocks in this sector [8] - Auna S.A. currently holds a Zacks Rank 5 (Strong Sell), indicating expectations of underperformance in the near future [6]

分组1 - Jack Henry reported quarterly earnings of $1.75 per share, exceeding the Zacks Consensus Estimate of $1.46 per share, and showing an increase from $1.38 per share a year ago, resulting in an earnings surprise of +19.86% [1] - The company achieved revenues of $615.37 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.50% and increasing from $559.91 million year-over-year [2] - Jack Henry has consistently surpassed consensus EPS estimates over the last four quarters, achieving this four times [2] 分组2 - The stock has underperformed the market, losing about 8.3% since the beginning of the year, while the S&P 500 has gained 9.7% [3] - The current consensus EPS estimate for the upcoming quarter is $1.65, with expected revenues of $642.22 million, and for the current fiscal year, the EPS estimate is $6.14 on revenues of $2.53 billion [7] - The Zacks Industry Rank indicates that the Computers - IT Services sector is currently in the bottom 39% of over 250 Zacks industries, which may impact stock performance [8]

Company Performance - La-Z-Boy reported quarterly earnings of $0.47 per share, missing the Zacks Consensus Estimate of $0.53 per share, and down from $0.62 per share a year ago, representing an earnings surprise of -11.32% [1] - The company posted revenues of $492.23 million for the quarter ended July 2025, surpassing the Zacks Consensus Estimate by 0.39%, but down from $495.53 million year-over-year [2] - Over the last four quarters, La-Z-Boy has surpassed consensus EPS estimates two times and topped consensus revenue estimates four times [2] Market Performance - La-Z-Boy shares have lost about 12% since the beginning of the year, while the S&P 500 has gained 9.7% [3] - The current consensus EPS estimate for the upcoming quarter is $0.72 on revenues of $533.1 million, and for the current fiscal year, it is $3.17 on revenues of $2.16 billion [7] Industry Outlook - The furniture industry, to which La-Z-Boy belongs, is currently in the bottom 9% of the Zacks industry rankings, indicating potential challenges ahead [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact La-Z-Boy's stock performance [5][6]

分组1 - Viking Holdings reported quarterly earnings of $0.99 per share, matching the Zacks Consensus Estimate, and up from $0.76 per share a year ago [1] - The company posted revenues of $1.88 billion for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 2.59%, compared to $1.59 billion in the same quarter last year [2] - Viking shares have increased approximately 36.6% year-to-date, outperforming the S&P 500's gain of 9.7% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $1.18 on revenues of $2 billion, and for the current fiscal year, it is $2.49 on revenues of $6.36 billion [7] - The Leisure and Recreation Services industry, to which Viking belongs, is currently ranked in the bottom 27% of over 250 Zacks industries, indicating potential challenges ahead [8]

Group 1 - Medtronic reported quarterly earnings of $1.26 per share, exceeding the Zacks Consensus Estimate of $1.23 per share, and showing an increase from $1.23 per share a year ago, resulting in an earnings surprise of +2.44% [1] - The company achieved revenues of $8.58 billion for the quarter ended July 2025, surpassing the Zacks Consensus Estimate by 2.50%, and up from $7.92 billion year-over-year [2] - Medtronic has outperformed the S&P 500 with a share price increase of about 16.2% since the beginning of the year, compared to the S&P 500's gain of 9.7% [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is $1.33 on revenues of $8.73 billion, and for the current fiscal year, it is $5.55 on revenues of $35.29 billion [7] - The Zacks Industry Rank indicates that the Medical - Products industry is in the top 39% of over 250 Zacks industries, suggesting that stocks in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8]

Core Viewpoint - JELD-WEN shows a significant improvement in earnings outlook, making it an attractive investment option as analysts continue to raise earnings estimates for the company [1][3]. Earnings Estimate Revisions - The rising trend in earnings estimate revisions reflects growing analyst optimism about JELD-WEN's earnings prospects, which is expected to positively impact its stock price [2]. - For the current quarter, JELD-WEN is projected to earn $0.25 per share, a decrease of 21.9% from the previous year, but the Zacks Consensus Estimate has increased by 8.57% over the last 30 days due to one upward revision [6]. - For the full year, the earnings estimate stands at $0.27 per share, representing a decline of 65.4% from the prior year, yet the trend remains encouraging with one upward revision and no negative revisions [7]. Zacks Rank and Performance - JELD-WEN has achieved a Zacks Rank 2 (Buy), indicating strong potential for outperformance based on favorable estimate revisions [8]. - Stocks with Zacks Rank 1 (Strong Buy) and 2 (Buy) have historically outperformed the S&P 500, suggesting a positive outlook for JELD-WEN [8]. Stock Performance - The stock has gained 37.6% over the past four weeks, driven by solid estimate revisions, indicating strong earnings growth prospects that may further elevate the stock price [9].

Core Viewpoint - Mineralys Therapeutics, Inc. (MLYS) has seen a 2% increase in share price over the past four weeks, closing at $14.52, with a potential upside of 149.7% based on Wall Street analysts' mean price target of $36.25 [1] Price Targets - The average price target consists of eight estimates ranging from a low of $15.00 to a high of $48.00, with a standard deviation of $11.25, indicating variability among analysts [2] - The lowest estimate suggests a 3.3% increase from the current price, while the highest estimate indicates a 230.6% upside [2] Analyst Sentiment - There is strong agreement among analysts regarding MLYS's ability to report better earnings than previously predicted, which supports the potential for stock upside [4] - Recent trends show that four earnings estimates have been revised higher in the last 30 days, with no negative revisions, leading to a 10.2% increase in the Zacks Consensus Estimate [12] Zacks Rank - MLYS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential for upside [13] Conclusion on Price Targets - While the consensus price target may not be a reliable indicator of the extent of MLYS's potential gains, it does provide a useful guide for the direction of price movement [14]

Core Insights - Zevra Therapeutics reported a quarterly earnings of $1.21 per share, which was below the Zacks Consensus Estimate of $2.19, resulting in an earnings surprise of -44.75% [1] - The company posted revenues of $25.88 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 14.35%, and showing significant growth from $4.45 million in the same quarter last year [2] - The stock has increased approximately 40.3% year-to-date, outperforming the S&P 500's gain of 8.4% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.06 on revenues of $24.48 million, while for the current fiscal year, the estimate is $1.36 on revenues of $94.1 million [7] - The estimate revisions trend for Zevra Therapeutics was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Drugs industry, to which Zevra Therapeutics belongs, is currently ranked in the top 35% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]